If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 12

A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors

Objective
The purpose of this study is to learn more about an investigational drug called DS-3939a. DS-3939a is an investigational drug that is not approved for your disease. It is being studied to see if it is safe and if your disease or medical condition improves while taking it.
Protocol No
DAIICHI-SANKYO-DS3939-077
Categories
Cancer, Prostate and Urologic Cancers, Kidney, Skin Cancers, Stomach, Uterine, Head and Neck Cancers, Esophagus, Thoracic Cancers, Ovary, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Prostate, Cervix, Gynecologic Cancers, Early Phase/Multiple Disease Site Cancers, Breast Cancers

A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors

Objective
A First-in-Human, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Protocol No
XILIO-XTX301-01-02-001
Categories
Cancer, Gynecologic Cancers, Thoracic Cancers, Colorectal, Early Phase/Multiple Disease Site Cancers, Kidney, Other Skin, Pancreas/Liver, Other Urologic, Prostate and Urologic Cancers, Stomach, Skin Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Sarcoma, Breast Cancers

A First-in-Human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients with Locally Advanced Un-Resectable and/or Metastatic Solid Tumors and Multiple Myeloma

Objective
Safety, PK and efficacy of QXL138AM in patients with solid tumors and multiple myeloma
Protocol No
NAMMI-QXL138AM-001
Categories
Cancer, Multiple Myeloma, Pancreas/Liver, Bladder, Breast Cancers, Kidney, Lung, Hematologic/Blood Related Cancers, Gastrointestinal Cancers, Thoracic Cancers, Prostate and Urologic Cancers

A Phase 1, Open-Label, Multicenter, First-in-Human Trial of DS3610A in Participants With Advanced Solid Tumors

Objective
A Phase 1 Study of DS3610A in participants with advance solid tumor cancer.
Protocol No
DAIICHI-DS3610-071
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Lip, Oral Cavity and Pharynx, Other Skin, Other Respiratory, Colorectal, Pancreas/Liver, Skin Cancers, Other Gynecologic, Other Gastrointestinal, Ovary, Prostate, Thoracic Cancers, Gastrointestinal Cancers, Sarcoma, Uterine, Kidney, Gynecologic Cancers, Breast Cancers, Eye/Orbital Cancers, Head and Neck Cancers, Other Urologic, Endocrine Cancers, Prostate and Urologic Cancers

A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol

Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203
Categories
Cancer, Bladder, Lung, Cervix, Lip, Oral Cavity and Pharynx, Gastrointestinal Cancers, Other Skin, Larynx, Kidney, Melanoma, Skin, Gynecologic Cancers, Thoracic Cancers, Skin Cancers, Breast Cancers, Head and Neck Cancers, Prostate and Urologic Cancers

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Subjects with KRAS G12C Mutant Advanced Solid Tumors

Objective
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Categories
Cancer, Kidney, Other Skin, Thoracic Cancers, Sarcoma, Gastrointestinal Cancers, Cervix, Prostate and Urologic Cancers, Other Gynecologic, Breast Cancers, Ovary, Gynecologic Cancers, Head and Neck Cancers, Early Phase/Multiple Disease Site Cancers, Endocrine Cancers, Melanoma, Skin, Eye/Orbital Cancers, Skin Cancers

Phase 1/2 Study of REGN15505 (a PSMAx4-1BB Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN4336 (a PSMAxCD3 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Ce

Objective
REGN15505 (PSMAx4-1BB) alone or in Combination with Cemiplimab or REGN4336 (PSMAxCD3) for Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Protocol No
REGENERON-R15505-ONC-24144
Categories
Cancer, Kidney, Prostate, Prostate and Urologic Cancers

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

Objective
To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Protocol No
INHIBRX-PH1-INBRX-106
Categories
Cancer, Other Gastrointestinal, Gynecologic Cancers, Kidney, Melanoma, Skin, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Thoracic Cancers, Early Phase/Multiple Disease Site Cancers